Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Annexon Biosciences
Biotech
Annexon's Guillain-Barré drug reduces disability in phase 3
Annexon’s ANX005 reduced disability in patients with the rare autoimmune disorder Guillain-Barré syndrome, meeting the main goal of a phase 3 trial.
Annalee Armstrong
Jun 4, 2024 9:21am
Annexon finds more silver linings in failed eye disease trial
Jul 31, 2023 10:05am
Pfizer exec out the door—Chutes & Ladders
Jul 28, 2023 9:30am
Annexon eye disease med failed phase 2 goal—the CEO is thrilled
May 24, 2023 4:01pm
Novavax CEO to retire after 12 years—Chutes & Ladders
Jan 13, 2023 9:30am
JPM23: Annexon looks for '2 ways to win' in Huntington's trial
Jan 11, 2023 12:55pm
